Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-04

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps

NCT07132827

Chronic Rhinosinusitis With Nasal Polyps

RECRUITING PHASE3

Dupilumab in Chinese Adult Participants With CRSwNP

NCT05878093

Chronic Rhinosinusitis With Nasal Polyps

COMPLETED PHASE3

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

NCT05873803

Chronic Rhinosinusitis with Nasal Polyps

ACTIVE_NOT_RECRUITING PHASE2

Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

NCT04805398

Chronic Rhinosinusitis (Diagnosis) Nasal Polyps

COMPLETED PHASE2

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

NCT06516302

Chronic Rhinosinusitis With Nasal Polyps

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Rhinosinusitis With Nasal Polyps

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Intervention Type DRUG

SHR-1905 Placebo Injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Weight ≥40kg
2. Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP).
3. Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril.
4. NCS ≥2 at screening and baseline.
5. SNOT-22≥20 at screening period and baseline.
6. Recorded persistent NP symptoms for over 4 weeks prior to screening.
7. Subjects received standard therapy with intranasal corticosteroids (INCS) and remained stable during the 4 weeks prior to randomization.
8. NP surgery in the past and/or ACERS treated with SCS occurred within 2 years before randomization (or with contraindications/ intolerances).

Exclusion Criteria

1. Any comorbidities that may affect the efficacy evaluation of nasal polyps.
2. Any comorbidities except for asthma that may affect blood EOS levels.
3. Concomitant with immunodeficiency.
4. Concomitant with contraindications or not suitable for nasal endoscopy.
5. Uncontrolled hypertension.
6. Uncontrolled diabetes.
7. Infection within 2 weeks prior to screening to randomization that is clinically significant and/or should be treated with systemic antibiotics.
8. Uncontrolled epistaxis within 4 weeks prior to randomization.
9. Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators.
10. Parasitic infection within 6 months before randomization.
11. Sinus or intranasal surgery (except for diagnostic biopsy) within 6 months prior to randomization, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible.
12. Malignancies diagnosed within 5 years before randomization (except those with a low risk of metastasis or death).
13. Abnormalities of laboratory tests at screening or baseline.
14. Concomitant with active hepatitis B, positive hepatitis C virus antibodies, positive human immunodeficiency virus antibodies, or positive treponema pallidum antibodies.
15. Prolonged QTc interval (\>450ms for male and \>470ms for female) or other clinically significant abnormal results of ECG at screening or baseline that may cause significant safety risks to subjects.
16. FEV1 before the use of bronchodilator (pre-BD) was less than 50% at screening.
17. Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization.
18. SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period.
19. Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure.
20. Adnimistration of live vaccine or viral vector vaccine within 4 weeks before randomization.
21. Allergen immunotherapy within 8 weeks before randomization.
22. Smoking history ≥10 pack-years, smoking at screening, or smoking cessation less than 6 months at screening.
23. Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization.
24. Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No